New results from an ongoing clinical trial suggest that an experimental vaccine may not keep melanomas from coming back after all. The vaccine targets tumors that express a gene called MAGE-A3, which is active in 65% of melanomas that have begun to spread. However, researchers will continue the phase III trial because even though this treatment does not work on melanomas broadly, it could still control a tumor subtype with a particular mutation. The results of the continued study are expected in 2015. In addition, the MAGE-A3 vaccine is being tested against non-small cell lung cancer in another phase III trial, and initial findings are expected in 2014.